The Best GLP-1 for Weight Loss in 2026: A Real Look at Efficacy, Side Effects, and What's Coming
Wegovy, Zepbound, Saxenda — and retatrutide on deck. Here's what the actual evidence says about each.
Now I have all the data I need. Let me write the article.
The GLP-1 landscape just got a formal 2026 scoreboard — and if you've been wondering which drug actually wins on weight loss, the evidence is more nuanced than any headline lets on.
What We're Actually Comparing
Three FDA-approved options dominate the conversation right now: Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide). A fourth — retatrutide — is moving fast through trials but isn't on pharmacy shelves yet.
Each works differently. MedlinePlus notes that more than 70% of U.S. adults are overweight or have obesity, which is exactly why the race to find the most effective drug matters so much to so many people. But "best" depends entirely on your health profile, your tolerance for side effects, and what your insurance will actually cover.
Efficacy: Who Moves the Scale Most?
Tirzepatide (Zepbound) is currently the headline number. The SURMOUNT-1 trial published in NEJM showed tirzepatide producing substantial reductions in body weight in adults with obesity — the highest doses delivering the largest losses. A 2025 body composition analysis from SURMOUNT-1 in Diabetes, Obesity & Metabolism dug deeper, tracking what kind of weight was actually lost.
Semaglutide (Wegovy) is no slouch. A 2025 indirect comparison published in Diabetes, Obesity & Metabolism looked specifically at tirzepatide 10 mg and 15 mg versus semaglutide 2.4 mg in patients with type 2 diabetes and obesity — finding tirzepatide generally associated with greater weight reduction, though the authors noted the comparison is indirect and should be interpreted carefully.
A broader BMJ network meta-analysis from 2024 compared multiple GLP-1 receptor agonists on glycemic control, body weight, and lipid profiles — useful if you want the big-picture ranking across drug classes.
Liraglutide (Saxenda), the oldest of the three, generally produces more modest weight loss and requires a daily injection instead of weekly. It's still a legitimate option for people who've tried and not tolerated the newer agents.
Side Effects: The Shared Playbook (With Some Differences)
All three share a core side-effect profile. The FDA's label for Wegovy lists nausea, diarrhea, vomiting, constipation, and abdominal pain as the most commonly reported reactions (≥5% of patients in clinical trials). The Zepbound FDA label lists the same GI symptoms, plus hair loss and injection site reactions. Saxenda's label adds headache and dizziness to the common list.
All three carry warnings for acute pancreatitis, acute gallbladder disease, and a boxed warning about thyroid C-cell tumor risk seen in animal studies. These are reported adverse events from clinical trials — not confirmed causal rates in the general population. Your prescriber knows your individual risk picture.
Zepbound is unique in one FDA-approved indication: it's also cleared to treat moderate-to-severe obstructive sleep apnea in adults with obesity — something neither Wegovy nor Saxenda currently carries.
What's Coming: Retatrutide
If you're watching the pipeline, retatrutide (Eli Lilly's triple-agonist targeting GIP, GLP-1, and glucagon receptors) is the next candidate. Two active trials are listed on ClinicalTrials.gov right now: a Phase 3 maintenance-of-weight study (NCT06859268) that's active but not recruiting, and a Phase 2 placebo-controlled trial (NCT07467447) that is currently recruiting. Early data has generated significant interest, though no FDA approval exists yet.
The Comparison That Actually Matters: Yours
A head-to-head trial between Wegovy and Zepbound in people without diabetes is not yet publicly available. The SURPASS-2 trial in NEJM compared them in type 2 diabetes patients — a different population with different metabolic dynamics. Extrapolating that directly to a person without diabetes is a stretch.
What does that mean practically? The "best" GLP-1 is the one you can access, afford, tolerate, and stay on. Efficacy numbers from trials assume full adherence at maximum tolerated doses — real-world results vary.
What this means for you:
- Tirzepatide (Zepbound) shows the largest weight-loss numbers in current trial data, but head-to-head evidence against semaglutide in non-diabetic adults is still limited — interpret comparisons cautiously.
- Side-effect profiles overlap significantly across all three approved drugs; GI symptoms are the most common reason people reduce or stop doses.
- Retatrutide is the one to watch in the pipeline, with active Phase 2 and Phase 3 trials underway — but it's not yet FDA-approved.
Not medical advice. Talk to your prescriber about which option fits your health history, goals, and coverage.
